BACKGROUND: Adherence to endocrine therapy for breast cancer is often inadequate, in part because of out-of-pocket costs for medication. Numerous states have enacted parity laws to limit patient cost-sharing for oral anticancer drugs. The objective of this study was to estimate the impact of these laws on patient copayments for and adherence to oral endocrine therapy for breast cancer. METHODS: Administrative health insurance claims data from 2007 to 2014 derived from a US health care database were used to identify female patients aged 18 to 64 years with invasive cancer or ductal carcinoma in situ of the breast who initiated endocrine therapy and were enrolled in fully insured health plans in states that either enacted parity legislation between 2008 and 2013 or had not yet enacted such legislation by 2015. Differences-in-differences analysis was used to compare copayments for and adherence to endocrine therapy during the 1-year period before and after each year of legislation enactment. RESULTS: In total, 6900 individuals who received 7778 unique drug therapy courses were identified. Parity legislation was associated with significant decreases in the 25th percentile of copayments for anastrozole of $4.39 (95% confidence interval [CI], −$4.52 to −$4.26; P < .001) and for exemestane of $3.08 (95% CI, −$4.80 to −$1.35; P < .001). The median copayment for exemestane decreased by $10.25 (95% CI, −$12.61 to −$7.89; P < .001). A higher median monthly copayment was significantly associated with a greater risk of medication nonadherence (adjusted risk ratio, 1.006 per dollar increase; P < .001). CONCLUSIONS: Parity laws had a modest effect on lowering the cost of anastrozole and exemestane, but more focused efforts to limit out-of-pocket costs for endocrine therapy may have a greater impact on medication adherence. Cancer 2019;125:374-381.
INTRODUCTION
Oral endocrine therapy is an integral component of hormone receptor-positive breast cancer treatment that has demonstrated the ability to lower the risk of disease recurrence and death.
1,2 Therefore, the National Comprehensive Cancer Network guidelines recommend adjuvant endocrine therapy with tamoxifen or an aromatase inhibitor, depending on menopausal status, for a minimum of 5 years after surgery for women who have early stage, estrogen receptor-positive breast cancer. 3 However, more than one-quarter of patients may be nonadherent to these therapies, in part because of out-of-pocket costs for medication. [4] [5] [6] Efforts to lower the cost-sharing burden of these drugs may improve therapy adherence and, ultimately, disease outcomes.
To date, 43 states and the District of Columbia have enacted oral parity laws that limit patient out-of-pocket costs for oral anticancer medications (typically covered under a patient's pharmacy benefit) to those for infused (intravenous) anticancer medications (typically covered under the medical benefit). 7 These laws apply only to state-regulated insurance plans (ie, fully insured plans) that do not fall under the Employee Retirement Income Security Act, and federal legislation is pending. 8 Although it has not been demonstrated that these laws consistently reduce out-of-pocket spending for oral anticancer medications exclusive of endocrine therapy, they have been associated with decreased spending for less expensive drugs. 9 The objective of the current study was to investigate whether parity laws have an impact on the cost of and adherence to endocrine therapies.
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MATERIALS AND METHODS

Cohort Selection
We performed a retrospective cohort study using national administrative health insurance claims data from 2007 to 2014 obtained from the Clinformatics Data Mart Database (OptumInsight, Eden Prairie, MN), which is a de-identified database from a large national insurance provider. This study was deemed exempt from review by the Institutional Review Board of Stanford University.
We selected female patients aged 18 to 64 years with a diagnosis of invasive cancer or ductal carcinoma in situ of the breast who were enrolled in fully insured commercial health insurance plans that were subject to state laws (Supporting Table 1 ). Oral endocrine therapy administration was identified from pharmacy claims using National Drug Codes for anastrozole, exemestane, letrozole, and tamoxifen (Supporting Table 2 ).
Our treatment group consisted of patients who resided in states that had enacted oral parity legislation between 2008 and 2013 (Supporting Table 3 ) and who had initiated oral endocrine therapy with an index claim either in the 12 months before January 1 of the year their respective state's law was enacted or in the 12 months after December 31 of the year the law was enacted. Our control group consisted of patients who resided in states that had not yet enacted oral parity legislation as of January 1, 2015 (Supporting Table 3 ) and who also had initiated oral endocrine therapy between 2007 and 2014. In addition, all patients were required to have continuous health plan enrollment over an 18-month period inclusive of the year of endocrine therapy initiation as well as at least 1 additional claim for the same drug within the same calendar year to allow accurate calculation of comorbidity indices and adherence measures, respectively.
Outcome Measures and Study Covariates
Our primary outcome on the claims level was the monthly copayment amount, which was normalized to a 30-day supply of medication and was exclusive of deductibles, given that an individual plan's deductible would not be specific to oral anticancer drugs and may have been met with other services. Furthermore, only a small proportion of claims (4%) in our sample had nonzero deductible payments. Coinsurance amounts were not available in the database. All prices were converted to real 2014 US dollars using the medical component of the US Consumer Price Index. On the patient-drug level, copayment amounts were summarized as the median of all claims for the same drug, normalized to a 30-day supply, for the same patient. Variable medication possession ratios (MPRs) were estimated on a per-patient, per-drug basis by calculating the ratio of the sum of days supplied divided by the number of days between the start of the first prescription and the scheduled end date of the last prescription (ie, prescription fill date plus number of days supplied). 11, 12 Patients who had an MPR ≥0.8 for a particular drug were considered adherent to that drug. 4, 6 Given the potential of overestimating true adherence rates using this methodology, we also performed a sensitivity analysis by calculating fixed MPRs using the ratio of the sum of days supplied divided by the number of days from the start of the first prescription to the end of the calendar year.
Statistical Analysis
Because some states enacted parity laws at different times during the study period, we performed a differencesin-differences analysis using data from the year before and the year after parity legislation was enacted in states that did so while using nonparity law states to provide controls for these before and after comparisons. 9, 13, 14 Details of this experimental design are presented in Supporting Figure 1 . Differences in baseline characteristics between states with and without parity laws were described and assessed using Pearson chi-square tests. Univariable quantile regression for each drug was used to compare median copayment amounts between prelaw and postlaw periods in states that enacting the law after changes to generic formulation. Multivariable quantile regression for the 25th, 50th, 75th, 90th, and 95th percentiles of copayment amounts for oral endocrine therapy was used to estimate the impact of parity law enactment for each drug separately using a differences-in-differences approach and adjusting for year, plan type, and geography. In addition, multivariable linear regressions with robust standard errors were performed to estimate the effect of parity law enactment on the mean copayment amount for each drug.
Poisson regression models with log link and robust standard errors were used to estimate the association between the median monthly copayment at the patient-drug level and nonadherence. Multivariable models were adjusted for drug type and demographic characteristics, including age, Charlson comorbidity scores, and year of treatment. Sensitivity analyses of adherence were performed using copayment dichotomized at $20 (a cutoff defined in previous research 5 ) and median monthly out-of-pocket spending (inclusive of copayment and deductible amounts). All tests were 2-sided with an α of .05. Statistical analyses were performed using SAS Cancer 
RESULTS
Patient Characteristics
We identified 6900 individuals who had 41,063 pharmacy claims and 7778 unique drug therapy courses, representing an average of 1.1 different drugs used per patient in the first year of endocrine therapy. The most prevalent therapy was tamoxifen (40% of all treatment courses). Approximately 21% of our cohort resided in states subject to parity legislation. Additional baseline characteristics are presented in Table 1 .
Copayment Costs
Median monthly copayment amounts for anastrozole, exemestane, letrozole, and tamoxifen were $10.95, $31.62, $21.90, and $10.51, respectively. During the study period, generic formulations for anastrozole, exemestane, and letrozole were introduced, whereas all pharmacy claims for tamoxifen in our study were for its generic formulation. Figure 1 characterizes the median monthly copayments for both brand and generic formulations of each drug in nonparity states and the change in copayments before and after law enactment in parity states. Median monthly copayments decreased significantly for generic formulations of each drug after parity legislation in states subject to the laws, with the greatest decrease for exemestane of $11.43 (P = .001). Absolute differences in median monthly copayments Cancer February 1, 2019 for generic anastrozole, letrozole, and tamoxifen were small (<$1.00; P < .001 for each).
On multivariable, differences-in-differences, quantile regression analysis, parity legislation was associated with significant decreases in the 25th percentile of copayments of $4.39 for anastrozole (95% confidence interval [CI], −$4.52 to −$4.26; P < .001) and $3.08 for exemestane (95% CI, −$4.80 to −$1.35; P < .001). Copayment at the 25th percentile increased $7.21 for letrozole (95% CI, $7.17 to $7.26; P < .001), but did not change significantly for tamoxifen (Table 2) . At the 50th percentile, copayment decreased $10.25 for exemestane (95% CI, −$12.61 to −$7.89; P < .001) after parity legislation. For the other drugs, estimates were effectively zero because of an overlap of the cumulative distribution functions of copayment at the 50th percentile before and after parity legislation (see Supporting Fig. 2 ). Additional analyses performed at the 75th, 90th, and 95th percentiles Figure 1 . The median monthly copayments for brand and generic formulations of each drug are illustrated by residence in states that are and are not subject to parity laws. An asterisk indicates that the difference was statistically significant at P < .05 on univariable quantile regression. Cancer February 1, 2019 also were effectively zero for the same reason. The use of dithering (ie, adding small, random perturbations to the copayment amounts) made no substantive difference to these estimates or conclusions. There also were no significant differences in mean copayment amounts associated with parity legislation for any of the 4 drugs (Supporting Table 4 ). We further investigated the potential differential impact of parity legislation on generic versus brand-name drugs. On subset differences-in-differences analyses evaluating only generic drugs, copayment was significantly lower after legislation for anastrozole at the 25th percentile and for exemestane at the 50th percentile (Supporting Table 5 ). On analyses evaluating only brand-name drugs, copayment was significantly lower after legislation for exemestane at the 25th and 50th percentiles and for letrozole at the 25th percentile (Supporting Table 6 ). Our results suggest that legislation was associated with lower copayment amounts for both generic and brand-name formulations but had a greater absolute impact on costs for brand-name drugs.
To test the assumptions of our differences-indifferences analysis, we also evaluated the change in copayment amounts for each drug across states separately only in the prelaw period and only in the postlaw period. There did not appear to be significant differences in the copayment quarterly trends for each drug across states in the prelaw-only period, suggesting that the differences observed after legislation enactment may be related to the policy itself (Supporting Fig. 3 ). In addition, we performed a placebo test by analyzing only claims in the postlaw period for states that enacted the laws and compared them with claims from our control states. There were no statistically significant differences in copayment amounts across states for any of the drugs between the first 6 months and the latter 6 months of the postlaw period (Supporting Table 7 ).
Adherence Outcomes
In our cohort, the proportions of patients who remained adherent during the first year of therapy to anastrozole, exemestane, letrozole, and tamoxifen were 92.7%, 92.1%, 91.3%, and 90.9%, respectively, as measured using the variable MPR methodology. Higher median monthly copayment was significantly associated with a higher risk of nonadherence (adjusted risk ratio [aRR], 1.006 per dollar increase; P < .001) ( Table 3) . Neither drug type nor the interaction between median monthly copayment and drug type were significantly associated with adherence. Grouping the 3 aromatase inhibitors into a single classification also did not change the results. Our analyses were supported by the outcomes of our sensitivity analyses (Supporting Table 8 and 9) . Monthly copayments ≥$20 were associated with a higher risk of medication nonadherence, but the difference did not reach statistical significance (aRR, 1.241; P = .058), whereas median total out-of-pocket spending, inclusive of deductible amounts, was significantly Cancer February 1, 2019 associated with a higher risk of nonadherence (aRR, 1.003; P < .001). By using the fixed MPR methodology, adherence rates for anastrozole, exemestane, letrozole, and tamoxifen were lower at 84.9%, 78.3%, 83.7%, and 84.7%, respectively. Higher median monthly copayment remained significantly associated with a higher risk of nonadherence even after using this alternative definition of adherence.
DISCUSSION
Parity laws regulating fully insured health plans have been enacted by a majority of states since 2008 to limit patient cost sharing for oral anticancer medications to an amount no greater than that for infused anticancer medications. However, given the differences in coverage for both infused and oral medications across various health plans, the effect that state laws have had on patient out-of-pocket spending for cancer therapy remains unclear. A federal bill, the Cancer Drug Coverage Parity Act, 8 was recently introduced in Congress to regulate self-funded plans that fall under the Employee Retirement Income Security Act, and an understanding of the impact of state laws will be important to the ongoing federal legislative debate. We used an administrative health insurance claims database from a large national insurer to perform a differences-in-differences analysis exploring the effects of parity legislation enactment on copayments for endocrine therapy in fully insured health plans. We observed that parity legislation significantly reduced monthly copayments for exemestane and anastrozole, but increased copayments for letrozole, in states subject to these laws compared with states that had not yet enacted parity legislation. Furthermore, reductions in monthly copayment amounts were significantly associated with a higher likelihood of adherence.
Prior research by Dusetzina and colleagues has suggested that the impact of state oral parity laws on the overall cost of drugs has been variable, with an estimated increase in out-of-pocket costs of approximately $150 per month for the top 5% most expensive drugs but a decrease of $20 per month for the lowest 25% of drugs after the enactment of parity legislation. 9 In addition, the proportion of drugs with $0 out-of-pocket costs in fully insured health plans increased from 15% to 53%, compared with 12% to 18% in self-funded plans. 9 These data interestingly suggest that parity laws may have a greater effect on reducing the cost of relatively less expensive drugs.
Oral endocrine therapies were not included in the aforementioned analysis, but the results of our current study are generally consistent with the finding by Dusetzina et al that parity laws decreased spending for drugs with baseline out-of-pocket costs <$50. 9 Only in states subject to parity laws, median monthly copayments decreased significantly for generic formulations of all 4 drugs after parity legislation, with the greatest decrease for exemestane of >$11. On multivariable differences-in-differences analysis controlling for residence in a state subject to parity laws, we observed that parity legislation significantly decreased the monthly copayment for exemestane, the endocrine therapy with the highest baseline cost, by $3.08 and $10.25 at the 25th and 50th percentiles, respectively. When considering brand-name formulations of exemestane only, the magnitude of these declines increased to $23.04 and $16.42, respectively.
Legislation enactment also was associated with decreased copayment for anastrozole by $4.39 and increased copayment for letrozole of $7.21 at the 25th percentile, but without any measurable difference at the 50th percentile for either drug. This suggests that the distribution of lesser copayments for anastrozole and letrozole changed as a result of the laws but did not change for the majority of prescription fills. It is unclear why copayments increased for letrozole without further details on the structure of each health plan's medical and pharmacy benefits. However, a possible explanation is that, for plans with initially favorable coverage of letrozole, perhaps through tiered pharmacy benefits, copayments were increased without exceeding the cost-sharing amount on medical services, thus satisfying parity with infused therapies, a concern that was previously introduced. 7 Given the concept of oral parity, these laws theoretically reduce patient spending only when the baseline outof-pocket cost for an oral drug exceeds the out-of-pocket cost for medical services that typically would be paid by the patient for receipt of an infused drug. With a median copayment of >$30 per month, exemestane possibly exceeded this threshold for most health plans included in our sample. Consequently, we observed the greatest decrease in patient spending for exemestane after the enactment of parity legislation. However, the impact of parity laws on patient out-of-pocket costs depends as much on a health plan's benefits structure as it does on a specific drug's market price or cost to the insurer. This may help to explain why we observed changes at the 25th and 50th percentiles, but not at the upper end of each distribution. One hypothesis is that the lower end of the endocrine therapy copay distribution in our sample comprised primarily health plans that had very favorable coverage of medical services, including infused chemotherapy, Cancer February 1, 2019 whereas the opposite was true at the upper end of the distribution. If this is true, then the greatest effect after parity legislation would be observed on drugs in health plans that had lower initial copayment amounts.
One analysis of health insurance claims data from privately insured, nonelderly patients indicated that annual out-of-pocket spending for targeted oral anticancer drugs between 2001 and 2011 was less than one-half of that for intravenous anticancer drugs, despite rising costs of oral drugs to the insurer. 15 Those authors hypothesized that the lack of significant coinsurance requirements for pharmacy benefits in the studied health plans contributed to these results. A report by the actuarial firm Milliman also concluded that health plans with pharmacy benefits that lack significant patient coinsurance would likely experience little effect from parity legislation given a low baseline cost-sharing burden on patients for oral drugs. 16 Similarly, the lack of coinsurance data in our database possibly underestimates the change in patient out-of-pocket costs, although the effect would be less for lower cost drugs.
Although endocrine therapies for breast cancer are typically less expensive than newer targeted anticancer therapies, their out-of-pocket costs still may create significant financial barriers to initial access and to therapy adherence. [4] [5] [6] [17] [18] [19] Rates of adherence to adjuvant endocrine therapy for breast cancer have been reported between 75% and 88% in the commercially insured population 5, 17, 20 are but as low as 63% in the Medicare population. 4, 21 In our commercially insured, nonelderly population, we observed adherence rates between 90% and 92% in the first year of endocrine therapy. Although our rates are higher than those reported in other studies, much of the discrepancy is likely related to differences in the definition of adherence. Unlike other studies that calculated MPRs over a fixed time interval, 4,5 we used variable MPRs 12 to observe the effects of copayment on adherence in the year before and the year after parity enactment without biasing against those who initiated therapy later in the year. However, this methodology, along with the inclusion only of patients who had at least 2 pharmacy fills within the first year of therapy, likely overestimates the true adherence rates in our study population. We performed additional analyses by recalculating adherence rates using the number of days from the first prescription to the end of the calendar year, and the results were are more consistent with prior research. However, this method may underestimate adherence by penalizing those who discontinued or switched therapy before the end of the year.
Nevertheless, consistent with previous research, [4] [5] [6] 19, 22, 23 we observed that higher copayments and total out-of-pocket costs, along with younger age and higher comorbidity scores, were associated with an increased risk of nonadherence to endocrine therapy using both methods to calculate adherence. Multiple studies have reported that out-of-pocket costs as low as $20 to $30 per month are associated with significantly lower adherence to these medications. 5, 6, 17 We estimate that a decrease in the monthly copayment of $10 may decrease the risk of nonadherence to endocrine therapy by 6%, whereas reducing the copayment below $20 may decrease the risk of nonadherence by >20%. Consequently, parity laws may have had a modest but beneficial effect on overall endocrine therapy adherence. Improved understanding and mitigation of the modifiable factors that influence endocrine therapy adherence may improve breast cancer outcomes, including recurrence risk, disease-free survival, and quality of life. [24] [25] [26] [27] Because some states enacted parity laws at different times during the study period, whereas other states had not enacted a law during that time, our study design leveraged the benefits of a natural experiment to control for unmeasured confounders. However, several important limitations to our study exist. Although our primary analyses focused on copayments, this outcome may not represent total patient out-of-pocket costs net of supplemental insurance and discounts. In addition, as discussed above, coinsurance details were not available in the database, and more detailed demographic and clinical information (such as disease stage or prior treatments) was not available for inclusion in our adjusted models. Finally, our analyses focused on secondary nonadherence only among patients who had at least 2 prescription fills. Because of the nature of claims data containing information on only filled prescriptions, we were unable to comment on the effect of copayment amounts on primary nonadherence (ie, not filling the initial prescription, which likely contributes to lower overall medication adherence). Further research is required to investigate these effects.
Despite these limitations, our current results can inform future discussions of state and federal oral parity legislation as well as other efforts to lower the out-of-pocket costs of anticancer drugs, and of endocrine therapies in particular. Parity laws appeared to have a modest effect on lowering the cost of exemestane and anastrozole. Although legislation appeared to lower copayments for both generic and brand-name formulations of exemestane, the absolute impact was greatest on copayments for
Cancer February 1, 2019 brand-name drugs given their high baseline cost. Lower copayments were associated with improved adherence across all drugs, and more focused efforts to limit outof-pocket costs for endocrine therapy may have a greater impact on medication adherence.
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